India's micronutrient gap is measurable and correctable. VitamyCare pairs biomarker analytics with evidence-based supplementation protocols, so each person receives the dose their blood work supports, within established safety limits.
Our mission
Sub-clinical deficiencies in vitamin D₃, B12, iron and folate stay invisible until their effects are hard to reverse. They hold back cognitive development, immune function and metabolic health across every age group and income level.
VitamyCare identifies and quantifies each deficiency from a blood panel, then corrects it with a protocol grounded in FSSAI Dietary Reference Values, FDA Dietary Reference Intakes and Pharmacy Council dispensing standards. No guesswork and no over-supplementation.
Every recommendation starts from the person's own serum results, never a one-size-fits-all dose.
Doses are capped at the FDA and FSSAI tolerable upper limits, with interactions screened before dispatch.
A registered pharmacist reviews each protocol before it reaches the patient, under Pharmacy Council norms.
Roadmap
Four stages, each gated by the regulatory milestone that has to be met before the next one begins.
Defining the core biomarker panel and reference ranges against ICMR-NIN 2020 nutrient requirements and NFHS-5 prevalence data. The model is trained only on consented, anonymised records under the DPDP Act.
Personalised formulations built to the FSSAI Health Supplements, Nutraceuticals Regulations 2022. Each batch carries a third-party certificate of analysis, heavy-metal profile and microbiological testing.
A controlled 12-week pilot tracking serum 25(OH)D, B12, haemoglobin and folate normalisation, plus patient-reported fatigue and cognitive clarity. The protocol is registered with CTRI.
Direct-to-consumer and clinic channels across India, with marketing claims held to FSSAI and ASCI norms and a pharmacovigilance process in place before the first shipment.
Micronutrient science
Recommended intakes and upper limits follow the FDA Dietary Reference Intakes and the FSSAI and ICMR-NIN Recommended Dietary Allowances for Indians. Select a nutrient to see what it does, how well it absorbs, where it comes from and what it interacts with.
The science
A panel of 12 to 18 serum and plasma markers, including 25(OH)D, B12, ferritin, TIBC, RBC folate, zinc and hs-CRP, is taken in a single blood draw at an NABL-accredited laboratory. Specimen handling follows CLSI guidance so results are comparable across sites.
The model measures the distance between each person's results and evidence-based optimal ranges. It accounts for age, sex, diet pattern, genetic factors such as MTHFR variants, existing conditions and current medication before proposing a nutrient plan.
Single-serving sachets carry exact doses in bioactive forms: cholecalciferol over ergocalciferol, methylcobalamin over cyanocobalamin. Known absorption conflicts are designed out. Calcium and iron are never combined, zinc and copper are balanced, and folate is paired with B12 so one cannot mask the other.
Adherence, symptoms and biomarker response are reviewed at regular intervals, and doses step down as levels normalise so no one drifts past an upper limit. Adverse event reports are collected and escalated through the channels FSSAI and CDSCO require.
Technology
Every layer, from biomarker intake to recommendation, is designed around the security, auditability and traceability that healthcare regulation in India expects.
Health data is pseudonymised and held behind an explicit consent layer, encrypted with AES-256 at rest and in transit, and stored on infrastructure located in India.
Each recommendation is logged with the reference ranges compared, the factors that drove it and any contraindication flags, and can be exported in HL7 FHIR format for audit.
Quality governance runs from raw-material certificate of analysis to finished-product release and post-market surveillance, with batch traceability under WHO GMP principles.
A registered pharmacist reviews every AI-generated protocol before dispatch, keeping a qualified human accountable for each recommendation, as Pharmacy Council norms expect.
An HL7 FHIR R4 integration layer ingests results from accredited diagnostic labs, normalises reference ranges and tracks change across repeat tests without manual entry.
Patients and pharmacists can file adverse event reports through the app. Reports are coded to MedDRA, triaged, and prepared for submission under FSSAI and CDSCO post-market requirements.
The opportunity
Most supplementation in India is self-directed and untested. VitamyCare closes that gap with a regulatory-first, data-driven approach that builds clinical trust from the first prescription.
Contact
For investor conversations, clinical enquiries or press, write to us and we will reply directly.
Pitch materials and diligence documents are available on request by email.
Questions about protocols, evidence base or study design are welcome by email.